Table 1.
Comparison of germline testing results from this study with similar recent UK‐based studies
| This study | Rust, 2018 9 | Rahman, 2019 10 | Rumford, 2020 11 | George, 2016 12 | Plaskocinska, 2016 13 | Flaum, 2020 14 | |
|---|---|---|---|---|---|---|---|
| Number of patients | 791 | 236 | 122 | 255 | 207 | 232 | 480 |
| Data collection dates | 02/2015–02/2021 | 2013–NR | 02/2015–04/2016 | 04/2016–04/2018 | 07/2013–11/2014 | 07/2013–06/2015 | 11/2017–11/2019 |
| Setting | AWMGS, Wales | Four centres across Scotland | UCLH, England | Imperial College Hospital, England | The Royal Marsden Hospital, England | East Anglian Genetics Services, England | North West of England |
| Testing criteria | High‐grade serous ovarian/fallopian tube/peritoneal cancer | Non‐mucinous ovarian cancer | High‐grade non‐mucinous ovarian cancer | Epithelial ovarian cancer | Non‐mucinous ovarian cancer | Newly diagnosed epithelial ovarian cancer | Non‐mucinous epithelial cancer of ovary/fallopian tube/peritoneum |
| Age (years) at diagnosis (or referral where appropriate) of patients with versus without pathogenic variant | 58.1 vs 67.7 (mean) | NR | 58 vs 62 (median) | 57.8 vs 62.9 (mean) | 53.9 vs 57.8 (mean) | 49.5 vs 66.1 (mean) | 53.1/60.5 (BRCA1/BRCA2) vs 60.5 (mean) |
| Germline pathogenic BRCA variant detection rate | 73 (9.2%) | 31 (13.1%) | 18 (14.8%) | 34 (13.3%) | 33 (15.9%) | 18 (7.8%) | 89 (18.5%) |
| Dosage variant rate | 2 (2.7%) | NR | NR | 2 (5.9%) | 4 (12.1%) | NR | NR |
| Founder variant rate | 2 (2.7%) | NR | 2 (11%) | 6 (17.6%) | NR | 0 (0%) | AKJ population excluded |
AKJ, Ashkenazi Jewish; NR, not reported.
Categorical data presented as number of patients (%).